Englander Institute for Precision Medicine

Publications

Found 692 results
Author Title [ Type(Desc)] Year
Journal Article
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L et al..  2023.  Apoptotic cell death in disease-Current understanding of the NCCD 2023.. Cell Death Differ. 30(5):1097-1154.
Stenzl A, Sternberg CN, Ghith J, Serfass L, Schijvenaars BJA, Sboner A.  2022.  Application of artificial intelligence to overcome clinical information overload in urological cancer.. BJU Int. 130(3):291-300.
Brendel M, Su C, Bai Z, Zhang H, Elemento O, Wang F.  2022.  Application of Deep Learning on Single-cell RNA Sequencing Data Analysis: A Review.. Genomics Proteomics Bioinformatics. 20(5):814-835.
Skaro M, Hill M, Zhou Y, Quinn S, Davis MB, Sboner A, Murph M, Arnold J.  2021.  Are we there yet? A machine learning architecture to predict organotropic metastases. BMC Med Genomics. 14(1):281.
Mak L, Meleshko D, Danko DC, Barakzai WN, Maharjan S, Belchikov N, Hajirasouliha I.  2023.  Ariadne: synthetic long read deconvolution using assembly graphs.. Genome Biol. 24(1):197.
Bhinder B, Gilvary C, Madhukar NS, Elemento O.  2021.  Artificial Intelligence in Cancer Research and Precision Medicine.. Cancer Discov. 11(4):900-915.
Elemento O, Leslie C, Lundin J, Tourassi G.  2021.  Artificial intelligence in cancer research, diagnosis and therapy.. Nat Rev Cancer. 21(12):747-752.
Elkhader J, Elemento O.  2022.  Artificial intelligence in oncology: From bench to clinic.. Semin Cancer Biol. 84:113-128.
Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI et al..  2020.  Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.. JAMA Oncol. 6(2):217-225.
De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P et al..  2019.  Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.. Clin Cancer Res. 25(13):3839-3846.
Otto L, Budde K, Kastenmüller G, Kaul A, Völker U, Völzke H, Adamski J, Kühn JP, Krumsiek J, Artati A et al..  2020.  Associations between adipose tissue volume and small molecules in plasma and urine among asymptomatic subjects from the general population.. Sci Rep. 10(1):1487.
Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, Lin T-Y, Liberatore K, Cizin DM, Cohen BM et al..  2023.  An atlas of substrate specificities for the human serine/threonine kinome.. Nature. 613(7945):759-766.
Kepp O, Bezu L, Yamazaki T, Di Virgilio F, Smyth MJ, Kroemer G, Galluzzi L.  2021.  ATP and cancer immunosurveillance.. EMBO J. 40(13):e108130.
Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S et al..  2023.  Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.. NPJ Precis Oncol. 7(1):113.
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y et al..  2020.  Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.. Nature. 585(7826):E20.
Hsiehchen D, Bucheit L, Yang D, Beg MShaalan, Lim M, Lee SS, Kasi PMurtaza, Kaseb AO, Zhu H.  2023.  Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.. Nat Commun. 14(1):7621.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2024.  Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 15(1):225.
Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang C-J et al..  2018.  Author Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.. Nat Genet. 50(5):764.
Santambrogio L.  2023.  Autoimmunity to the modified self.. Science. 379(6637):1092-1093.
Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, Drozenova J, Fredriksen T, Hraska M, Hrnciarova T et al..  2022.  An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.. Clin Cancer Res. 28(14):3053-3065.
Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, San Pedro JManuel Bra, Cadwell K, Cecconi F, Choi AMK et al..  2021.  Autophagy in major human diseases.. EMBO J. 40(19):e108863.
Yamazaki T, San Pedro JManuel Bra, Galluzzi L, Kroemer G, Pietrocola F.  2021.  Autophagy in the cancer-immunity dialogue.. Adv Drug Deliv Rev. 169:40-50.
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Sridhar SS, Powles T, Durán MÁCliment, Park SHoon, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB et al..  2024.  Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.. Eur Urol. 85(2):154-163.
Grivas P, Agarwal N, Pal S, Kalebasty ARezazadeh, Sridhar SS, Smith J, Devgan G, Sternberg CN, Bellmunt J.  2021.  Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.. Cancer Treat Rev. 97:102187.